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Seizure is the most common neurologic medical disorder in the pediatric population. Almost 5% of healthy children experience at least one convulsive episode in their lifetime 
with onset during childhood in more than half of the cases [1]. The 
current evidence suggests that prolonged seizures are best stopped 
with early treatment [2]. Intravenous midazolam and lorazepam 
are now used as the first line of therapy in many hospital settings, 
although intravenous access is not available, intramuscular 
paraldehyde is an alternative in many parts of world [2,3]. Early 
domiciliary treatment of seizures in the community, school, or 
home with drugs that can be administered by parents, teachers, or 
non-medical staff may be beneficial and can decrease morbidity 
and mortality [2].
Outside the hospital, where intravenous and intramuscular 
therapy may be difficult or impossible to administer, rectal 
diazepam is being used as the primary treatment option for 
breakthrough seizures till now. However, it has a slow onset of 
action as compared to its intravenous route and is not effective 
at controlling seizures. Other disadvantages include the lower 
social acceptability of the rectal route and serious side effects 
like respiratory depression. The potential alternative method of 
benzodiazepine delivery is buccal route.
Recent studies have demonstrated INM to be effective in the 
management of acute childhood seizures [4-8]. However, it has 
been found that buccal administration and sublingual delivery 
being practiced in European countries are difficult to use when the 
teeth are clenched during a tonic-clonic seizure [9]. In the light of 
the above background, the present study was undertaken to assess 
the efficacy and side effects of INM in the treatment of acute 
childhood seizures in semi-urban/rural settings in North India.
MATERIALS AND METHODS
The present cross-sectional study was carried out by the department 
of pediatrics in a government medical college over a period of 
6 months. A written consent was obtained from the parents or 
guardians of children regarding their willingness to participate in the 
study. The study was approved by the Institute Ethical Committee.
A total of 50 children in the age group of 6 months–14 years 
with the previous history of convulsions were included in this 
study. The children who had upper respiratory tract infection with 
large amount of mucus secretions or had bleeding from nose were 
excluded from the study. The children who had metabolic cause 
of seizure activity or had seizure lasting for <3 min and more 
than 30 min were also excluded from the study. For abortion 
of seizures at home, INM was used by the parents in a dose of 
0.2 mg/kg (maximum dose: 10 mg) by puff inhalation method. 
The technique of drug administration was demonstrated to the 
parents/attendants beforehand in the outpatient department and 
ward. Further, this technique was cross-checked by demonstration 
in front of researcher and office independent colleagues (one PG 
student and one nurse).
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The parents or guardians were instructed to place the child 
in the recovery position during the seizure episode and to wait 
for 3 min before giving INM at home in both the nostrils. They 
were instructed to check the expiry of the spray. They were also 
told about the need of the second spray of INM. The parents were 
asked to report to the hospital immediately after that. The data 
were collected and then analyzed for the purpose of the study.
RESULTS
A total of 50 patients were further divided into three 
groups depending on their age: Group A consisted of 
6 months–4 years, Group B consisted of 4–9 years, and 
Group C comprised 9–14 years. Maximum number of the 
patients belonged to Group C (38%) followed by in Group B 
(36%) and Group A (26%). Etiologies of epileptic conditions 
of the children included in the study have been given in 
Table 1. The most common seizure type observed was generalized 
tonic-clonic in all three age groups [Table 2]. Most of the patients 
had seizures between 10 and 20 min (54%) at home. Group A 
had the longest seizure duration at presentation and the shortest 
duration was seen in Group B. The average duration of seizures 
at presentation was 14.65 min. The average duration of seizures 
before administration of INM was 16.22 min.
Seizure termination was quickest in Group A (4.46 min) and 
slowest in Group B (4.97 min). The average time for seizure 
termination was 4.66 min. Seizures were controlled within 5 min 
of INM in 37 patients and between 5 and 10 min in 8 patients. 
Repeat dose of INM was given in 13 patients; out of which, 
8 patients responded. Repeat dose was required mostly in Group B 
and least in Group C. The mean duration after which INM was 
repeated was 4 min.
Seizures were present 10 min after receiving INM in five 
patients and they were immediately brought to the emergency at the 
nearest district hospital and further treatment was carried out. There 
was minimal or no side effect of INM use. Common difficulties 
encountered at home during administration of INM were excessive 
nasal secretions, head movements, and sneezing [Table 3].
DISCUSSION
Seizures in children are the most frequent neurologic disorder 
affecting children. As prolonged seizure activity impacts 
morbidity and mortality, effective methods for seizure control 
should be instituted preferably before arrival at the hospital. 
Since parenteral methods of drug delivery are not available to 
caregivers at home, alternatives like midazolam have been tried 
sublingually (buccal) in European countries and intranasally in 
rest of the world. Nasal administration has an advantage of rapid 
absorption into systemic circulation without the disadvantage of 
passage through the portal circulation.
O’Regan et al. were the first in the literature to state 
the effectiveness of INM in acute epileptic seizures. They 
determined that 15 out of 19 patients had positive response as 
a dramatic improvement in electroencephalogram or cessation 
of convulsions [10]. In our study, it was observed in 45 out of 
50 patients after INM. The most common seizure type was 
generalized tonic-clonic (46%) followed by complex partial 
seizures (32%). While in a study done by Kutlu et al., 44% of 
patients had generalized tonic-clonic, 22% had complex partial, and 
22% of patients had secondary generalized partial seizures [11].
The average time of cessation of seizures after therapy was 
4.66 min which is in contrast to the study done by Lahat et al. 
where a total mean time to abort seizures was 6.1±3.6 min [6] 
while Lather et al. found the median duration to be 2.5 min [12].
In Fisgin et al. study, the response period following INM was 
1 min in 22% of patients, 1–2 min in 39% of patients, 2–5 min in 
22% of patients, and 5–10 min in 4% of patients. Seizures were 
present in 13% of patients after 10 min, while in our study, 10% 
of patients were having convulsions at 10 min after receiving 
INM. Seizures stopped in 5 min in 74% of patients and in 10 min 
in 90% of patients. Fisgin et al. had a response rate of 87% in 
10 min [5], while Harbord and Kyrkou had a response rate of 89% 
in their study done over 22 patients [13].
In a study done by Lather et al., 72% of patients responded 
to INM, while 28% of patients did not respond to INM use [12]. 
Table 1: Etiology of epileptic conditions included in the study
Diagnosis Number (%)
Epilepsy (Idiopathic) 17 (34)
Inflammatory granuloma (neurocysticercosis) 18 (36)
Febrile seizures 4 (8)
Tuberous sclerosis 4 (8)
West syndrome 7 (14)
Table 2: Seizure classification according to ILAE
Seizure type Number 
Generalized tonic-clonic 23
Right-sided focal seizures with impaired awareness 10
Left-sided focal seizures with impaired awareness 6
Focal seizures with awareness 2
Myoclonic 9
Table 3: Clinical characteristics with drug used
Characteristics Outcome
Age 6 months–4 years=13
4–9 years=18
9–14 years=19
Gender M=29, F=21
Average duration of seizure before 
therapy 
17 min
Average time of cessation seizure 
after therapy
4 min
Common difficulties during 
administration 
Excessive nasal 
secretion=6
Excess head movement=5
Number of patients requiring repeat 
doses 
11
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Wilson et al. carried out a telephone survey to evaluate the 
effectiveness of INM to terminate seizures in the settings outside 
the hospital. About 83% of families who had used it found it 
effective and easy to use [14]. Effectiveness and safety of non-
rectal and non-IV benzodiazepines were also supported by a 
study done by Haut et al. [15].
Urgent treatment is required for status epilepticus as 
neurologic complications are related to the duration of seizure. 
Chin et al. concluded that early treatment of status epilepticus 
decreased the need for intensive care unit admissions [16]. INM 
is thus an acceptable treatment option as a first aid response for 
acute seizures. There were few limitations of our studies. The 
sample size was small and the study was highly dependent on the 
parent’s reporting.
CONCLUSION
It is concluded that INM is safe and efficacious in aborting 
seizures at home by caregiver in semi-urban and rural settings. 
Future studies with larger sample size are required to establish 
the findings.
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